Novo Nordisk today officially acquired 100% of the shares of Biocorp, the France-based drug delivery device maker’s CEO announced. Biocorp designs, develops and manufactures drug delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors. The Mallya smart sensor attaches directly to insulin pen injectors to make them […]
Novo Nordisk
Ypsomed concludes autoinjector supply deal with Novo Nordisk
Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its […]
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Once-weekly insulin from Novo Nordisk meets clinical trial endpoints
Novo Nordisk announced data that met primary endpoints from clinical trials investigating its once-weekly basal insulin icodec. While meeting primary endpoints, the studies also demonstrated reduced injections. These injections decreased from seven to one per week with once-daily basal insulin. Novo Nordisk presented results at the 83rd Annual Scientific Sessions of the American Diabetes Association […]
Novo Nordisk looks to acquire a majority stake in BioCorp for $164.5M
Novo Nordisk announced today that it entered into exclusive negotiations for a controlling stake in drug delivery device maker Biocorp. France-based Biocorp specializes in the design, development and manufacturing of delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors. Mallya, a smart sensor, attaches directly to insulin […]
Novo Nordisk, Aspect Biosystems ink $75M deal for diabetes treatments
Aspect Biosystems and Novo Nordisk today announced a collaboration, development and license agreement around diabetes and obesity treatments. The agreement focuses on bioprinted tissue therapeutics designed to replace, repair or supplement the body’s biological functions. Novo Nordisk and Aspect aim to deliver a new class of disease-modifying treatments for diabetes and obesity. It leverages Aspect’s […]
Novo Nordisk to lower pre-filled insulin device prices by up to 75%
Novo Nordisk announced today that it plans to lower U.S. prices of several insulin products by up to 75% for those with type 1 and type 2 diabetes. Products include pre-filled insulin pens and vials of basal, bolus and pre-mix insulins. These specifically include Levemir, Novolin, NovoLog and NovoLog Mix 70/30. Novo Nordisk also plans […]
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
Amalgam Rx, Novo Nordisk expand partnership on connected insulin delivery devices
Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check. Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin. The two companies partnered to incorporate and integrate […]
Abbott FreeStyle LibreLink app now pairs with Novo Nordisk insulin pens in UK
Novo Nordisk (NYSE:NVO) announced that users of the Abbott (NYSE:ABT) FreeStyle LibreLink app can connect to its smart insulin pens. People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. Users of the Abbott FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology can see a […]
